Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …

Antibodies are the cardinal effector molecules of the immune system and are being
leveraged with enormous success as biotherapeutic drugs. A key part of the adaptive …

Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …

Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …

The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 immediately caused …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

Summary Recently emerged SARS-CoV-2 Omicron subvariant, BA. 2.75, displayed a growth
advantage over circulating BA. 2.38, BA. 2.76, and BA. 5 in India. However, the underlying …

The Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
outcompeted previously prevalent variants and become a dominant strain worldwide. We …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell
responses that continue to evolve for at least a year. During that time, memory B cells …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …